CZR vs MCRI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MCRI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CZR and MCRI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CZR and MCRI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Caesars Entertainment operates roughly 50 domestic gaming properties spread across the Las Vegas Strip and regional US markets, along with hotels, restaurants, entertainment venues, and its Caesars Digital segment (Caesars Sportsbook plus online iGaming across dozens of jurisdictions). Las Vegas and regional casinos each contribute close to half of property EBITDAR, and the digital business, though smaller, is the main growth engine: Q1 2026 digital net revenue set a first-quarter record near $374 million with adjusted EBITDA up sharply year over year. The company carries a heavy balance sheet, roughly $11.9 billion of gross debt and about $11.0 billion net, plus large annual lease obligations, so deleveraging has been a central management priority. Second-quarter 2026 revenue was about $2.99 billion, up about 3% year over year, with a net loss of about $62 million.

Full CZR guide

Monarch Casino & Resort, Inc. owns and operates two casino resorts under a premium, service-focused model: the Atlantis Casino Resort Spa in Reno, Nevada, and the Monarch Casino Resort Spa Black Hawk near Denver, Colorado. Revenue comes from three main buckets: casino gaming (slots and table games), hotel rooms, and food and beverage, with the spa, retail, and amenities rounding out a full-resort experience. Unlike sprawling national operators, Monarch concentrates all of its effort on maximizing the returns of just two owned properties, which is why it consistently posts some of the higher operating margins in regional gaming. The Farahi family founded and still helps run the company, giving it an owner-operator culture built around cost control and reinvestment in the physical assets.

Full MCRI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CZR drivers: Pending Fertitta cash acquisition; Caesars Digital growth.
• MCRI drivers: Two premium properties and margin discipline; Black Hawk growth near Denver.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest risk is deal-specific: a failure or renegotiation of the Fertitta acquisition, driven by regulatory or gaming-license setbacks (the merger has no financing condition), could send shares back toward the lower unaffected pre-rumor level. For MCRI, the most immediate company-specific risk is the PCL Construction litigation tied to the Black Hawk expansion, which has produced a judgment and recorded liability in the tens of millions (a roughly $74.6 million principal judgment and a litigation liability near $78.5 million) now under appeal; an adverse final outcome would be a real cash cost even though the balance sheet can absorb it.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CZR if you believe its drivers more; MCRI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CZR and MCRI guides.

CZR. CZR trades close to the $31.00 all-cash offer from Fertitta, so its market value of roughly $5.9 billion reflects deal terms more than a standalone multiple. On an enterprise basis the transaction values the company near $17.6 billion including assumed debt. Reported net income remains negative (Caesars has missed EPS estimates in each of the last four quarters) because interest and lease costs exceed operating profit, so investors focus on adjusted EBITDA, leverage, and deal-completion probability. Third-quarter results are due October 27, 2026.

MCRI. Figures are approximate and tied to the asOf date; verify live numbers before acting. After a strong 2026 run (up about 19% year to date), Monarch trades near 18x trailing and 17x forward earnings, a lower multiple than mid-year because earnings rose faster than the stock and the shares slipped about 6% over the past month. The recorded litigation liability is a real potential cash outflow that valuation frameworks should treat separately from ongoing operating earnings. The mean analyst target is about $126.50 with a hold rating, and third-quarter results on October 27, 2026 (consensus EPS about $1.70 on $148.7 million of revenue) are the next data point.

Headline figures (approximate, October 2026): CZR shows revenue (ttm) ~$11.65B, q2 2026 revenue ~$2.99B (+3% YoY), q2 2026 eps ~-$0.19 vs ~$0.13 expected, net income (ttm) ~-$465M; MCRI shows revenue (ttm) ~$562 million (Q2 2026 was ~$142.6 million, up ~4% year over year), net income (ttm) ~$115 million (Q2 2026 ~$32.5 million), diluted eps (q2 2026) ~$1.85 (beat estimates near $1.71), operating margin (ttm) ~27%, with net margin ~20%.

CZR and MCRI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CZR and MCRI exposure against your real portfolio. It is not an investment adviser.